Actinium Pharma (ATNM) Appoints June Almenoff to its Board

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to numerous biopharma companies.

Andes Seth, Actinium's Chairman and CEO, stated, "Through her career, June has amassed significant experience in translational research, drug development and business development that has resulted in multiple approved products and value creation. Her experience will be invaluable to Actinium and we are delighted to add Dr. Almenoff to the Actinium Board."

You May Also Be Interested In

• Betterware de Mexico, S.A.B. de C.V. (BWMX) files for 2.24M share offering by selling stockholders
• Lyntris (LYNX) files for 24M share IPO at $19-$22/sh
• L3Harris opens $6M naval training facility in Providence, R.I.